# Synbiotic as an Adjuvant Therapy for Dyslipidaemia and Gut Health

Study · id `cardio:ct-nct07915687` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07915687](<https://clinicaltrials.gov/study/NCT07915687>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07915687

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 190 participants.

## Technical summary

Registry record NCT07915687. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-02 (anticipated); primary completion 2027-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 190 participants (planned count; ClinicalTrials.gov record NCT07915687, source copy `cardio:ctgov-nct07915687-2026-11-05`, retrieved 2026-11-18)
- Planned start: 2026-12-02 (anticipated) (ClinicalTrials.gov record NCT07915687, source copy `cardio:ctgov-nct07915687-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT07915687, source copy `cardio:ctgov-nct07915687-2026-11-05`, retrieved 2026-11-18)
- Completion: 2028-06-01 (anticipated) (ClinicalTrials.gov record NCT07915687, source copy `cardio:ctgov-nct07915687-2026-11-05`, retrieved 2026-11-18)
- Countries: Malaysia (ClinicalTrials.gov record NCT07915687, source copy `cardio:ctgov-nct07915687-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07915687-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: Synbiotic as an Adjuvant Therapy for Dyslipidaemia and Gut Health
- Condition: Dyslipidemia
- Intervention (Dietary supplement): Synbiotic (LAB12 and SWEOAT® Bran)
- Intervention (Other): Oat-based Placebo
- Lead sponsor: Universiti Teknologi Mara
- Lead sponsor class: OTHER
- Collaborator: Dong Foong Manufacturing Sdn. Bhd.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: f1438678b55a54aebc4e91e4356ba6d45e170b574f572a8de1c6cbb01010d91b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
